BORTEZOMIB PLUS DEXAMETHASONE IN COMBINATION WITH MELPHALAN OR CYCLOPHOSPHAMIDE IN THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Tsirigotis, P. [1 ]
Girkas, K. G. [1 ]
Giannopoulou, V. [1 ]
Chondropoulos, S. [1 ]
Ioannidou, E. [1 ]
Papaxoinis, G. [1 ]
Pappa, V. [1 ]
Vasilatou, D. [1 ]
Dimoula, K. [1 ]
Kapodistrias, N. [1 ]
Papageorgiou, E. [1 ]
Economopoulos, T. [1 ]
Dervenoulas, J. [1 ]
机构：
[1] ATTIKON Gen Univ Hosp, Athens, Greece
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1109
引用
收藏
页码：436 / 436
页数：1
相关论文
共 50 条
  • [1] Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma
    Reece, Donna E.
    Trieu, Young
    Masih-Khan, Esther
    Atenafu, Eshetu G.
    Chen, Christine
    Prica, Anca
    Tiedemann, Rodger
    Trudel, Suzanne
    Kukreti, Vishal
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (07): : 387 - 394
  • [2] Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.
    Monge, Jorge
    Kortuem, K. Martin
    Stewart, A. Keith
    Bergsagel, P. Leif
    Mikhael, Joseph
    Reeder, Craig B.
    Mayo, Angela
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Clinical Efficacy of a Bortezomib, Cyclophosphamide and Dexamethasone Compared with Bortezomib, Cyclophosphamide, Thalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Moon, Joon Ho
    Sohn, Sang Kyun
    Jung, Sung-Hoon
    Bae, Soo-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BLOOD, 2011, 118 (21) : 815 - 815
  • [4] Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma
    Romano, A.
    Chiarenza, A.
    Consoli, U.
    Conticello, C.
    Forte, S.
    Uccello, G.
    Vetro, C.
    Cavalli, M.
    Coppolino, F.
    Palumbo, G. A.
    Di Raimondo, F.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1038 - 1044
  • [5] Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma
    Schmielau, J
    Teschendorf, C
    König, M
    Schmiegel, W
    Graeven, U
    LEUKEMIA & LYMPHOMA, 2005, 46 (04) : 567 - 569
  • [6] Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Wakabayashi, Masashi
    Tsukasaki, Kunihiro
    Miyamoto, Kenichi
    Maruyama, Dai
    Yamamoto, Kazuhito
    Takatsuka, Yoshifusa
    Kusumoto, Shigeru
    Kuroda, Junya
    Ando, Kiyoshi
    Kikukawa, Yoshitaka
    Masaki, Yasufumi
    Kobayashi, Miki
    Hanamura, Ichiro
    Asai, Hiroaki
    Nagai, Hirokazu
    Shimada, Kazuyuki
    Tsukamoto, Norifumi
    Inoue, Yoshiko
    Tobinai, Kensei
    CANCER SCIENCE, 2018, 109 (05) : 1552 - 1561
  • [7] EFFICACY OF THE COMBINATION THERAPY OF LIPOSOMAL ADRYAMICIN, BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ABCD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
    Romano, A.
    Chiarenza, A.
    Gorgone, A.
    Schinocca, L.
    Uccello, G.
    Cavalli, M.
    Fiumara, P.
    Motta, G.
    Palumbo, G.
    Di Raimondo, F.
    HAEMATOLOGICA, 2012, 97 : 607 - 607
  • [8] CONTEMPORARY INTRAVENOUS INJECTION OF BORTEZOMIB, MELPHALAN AND DEXAMETHASONE IN REFRACTORY AND RELAPSED MULTIPLE MYELOMA
    Romano, A.
    Chiarenza, A.
    Consoli, U.
    Conticello, C.
    Forte, S.
    Vetro, C.
    Uccello, G.
    Cavalli, M.
    Fiumara, P.
    Palumbo, G.
    Di Raimondo, F.
    HAEMATOLOGICA, 2012, 97 : 613 - 614
  • [9] EFFICACY AND SAFETY OF BORTEZOMIB PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Sanchez, R. Garcia
    Saldana, R.
    Caparros, I.
    Gallardo, A.
    Garcia-Delgado, R.
    Rosell, A.
    Campos, A.
    de Llano, M. P. Queipo
    Perez, I.
    Moreno, M. J.
    Del Castillo, S.
    De la Torre, S.
    Ramirez, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 500 - 500
  • [10] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
12345